| Popis: |
IL-13 is one of many cytokines responsible for the chronic inflammation of asthma. Increased values of IL-13 leads to airway hyperresponsiveness, mucus hypersecretion, activation of fibroblasts and hyperplasia and hypertrophy of smooth muscle of the airways and may cause irreversible airway remodeling. The aim of this study was to determine the effect of combined therapy of ICSs/LABAs plus Montelucast in patients with asthma, by analyzing of IL-13 and Symptom Score at the beginning and after 6 months of therapy. The study included 29 patients with severe asthma. In each of them were measured serum IL-13 levels by the ELISA method at the beginning and after 6 months of therapy. They were treated with combined therapy of ICSs/LABAs(500/50mcg-twice daily) plus Montelucast (10mg-daily) in duration of 6 months and assessing symptom scores with 5-point Likert scale of breathlessness at the beginning and after 6 months of therapy. The results were statistically elaborated according to the Wilcoxon Pairs Test. The obtainedresults of IL-13showedthat the level ofIL-13beforethe start of therapywere much higherandthattreatmentsignificantlyreduces theirvalue(Z=4,7; p=0,000003; p significant improvements ( Z=4,54; p=0,000006) Conclusion: The addition of anti-leukotrienes in regular preventive therapy with ICSs/LABAs, leading to reduced inflammation and certainly clinical and subjective improvement which is a therapeutic option and a step towards achieving total control of asthma. This suggests that IL-13 is an important marker for monitoring of evolution and success of therapy in patients with asthma. |
